Recap: TScan Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
TScan Therapeutics (NASDAQ:TCRX) reported Q3 earnings, beating estimated earnings by 46.67% with an EPS of $-0.24 versus an estimate of $-0.45. Revenue was up $524 thousand from the same period last year. Last quarter, the company beat EPS estimates by $0.27, which was followed by a 1.9% drop in the share price the next day.
November 09, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TScan Therapeutics reported better than expected Q3 earnings, but past performance shows a drop in share price following a beat on EPS.
TScan Therapeutics has reported better than expected earnings for Q3, which is generally a positive signal. However, the company's share price has previously dropped following a beat on EPS, indicating that investors may have different expectations. Therefore, the impact on the stock price in the short term is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100